Wendell David Associates Inc. Trims Holdings in IDEXX Laboratories, Inc. $IDXX

Wendell David Associates Inc. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,068 shares of the company’s stock after selling 1,245 shares during the period. Wendell David Associates Inc.’s holdings in IDEXX Laboratories were worth $6,219,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth $26,000. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $29,000. WealthCollab LLC acquired a new stake in IDEXX Laboratories during the second quarter worth about $30,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in IDEXX Laboratories during the third quarter worth about $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on IDXX. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. UBS Group cut their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Finally, Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Trading Down 1.8%

Shares of IDXX stock opened at $526.44 on Wednesday. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The firm has a market cap of $41.53 billion, a PE ratio of 38.77, a price-to-earnings-growth ratio of 2.93 and a beta of 1.55. The company has a 50-day moving average of $556.85 and a two-hundred day moving average of $611.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.